Skip to main content
. 2017 Feb 10;40(5):387–397. doi: 10.1007/s40264-017-0506-5

Table 3.

Prevalence of neurodevelopmental disorders and crude and adjusted odds ratios by antiepileptic drug group: study by the Liverpool and Manchester Neurodevelopment Group (adapted from Bromley et al. [2], with permission)

AED exposure during pregnancy Total (n) No. with NDD Prevalence of NDD [% (95% CI)] Unadjusted odds ratio Adjusted odds ratioa (95% CI) p value
Controls 214 4 1.87 (0.60–5.03) Reference Reference
WWE no AED 26 0 0.00 (0.00–16.02)
Carbamazepine 50 1 2.00 (0.10–12.01) 1.07 1.09 (0.06–7.39) 0.9
Lamotrigine 30 2 6.67 (0.00–23.51) 3.75 4.06 (0.55–22.20) 0.1
Valproate 50 6 12.00 (4.97–25.00) 7.16 6.05 (1.65–24.53) 0.007
Other monotherapy 14 2 14.29 (0.00–43.85) 8.75 8.17 (1.09–49.40) 0.02
Valproate polytherapy 20 3 15.00 (3.96–38.86) 9.26 9.97 (1.82–49.40) 0.005
Other polytherapy 11 1 9.09 (0.48–42.88) 5.25 4.95 (0.25–40.45) 0.2

Null cells result from either no observations or instability of the model due to small numbers

AED antiepileptic drug, CI confidence interval, NDD neurodevelopmental disorder, WWE women with epilepsy

aVariables used in exploratory analysis for consideration in the final model included seizures during pregnancy, maternal IQ, maternal age, socioeconomic status, alcohol or nicotine exposure, sex and gestational age at birth; a significant association was only found for sex [2]